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Hepatitis C is a serious public health problem throughout the world; chronic renal patients are
highly exposed to this infection. This could be due to a failure to identify carriers of this disease
or because of a lack of truly effective biosafety measures implemented in the dialysis units.
Molecular biology techniques have allowed for the understanding of this virus in detail, including
its replication mechanisms. Epidemiological studies have been made throughout the world, with
the goal of determining the dissemination dynamics of this agent, in addition to examining the
predominance of the different genotypes, and the possible mutants that are involved. Many questions
must still be answered concerning infection by Hepatitis C virus (HCV); this is especially important
for immunosuppressed patients.
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With technological advances in studies concerning
the Hepatitis C virus (HCV), the elaboration and the
implementation of diagnostic tests, such as triage in
blood banks that began in 1990, has allowed
professionals to understand the dimension of the
Hepatitis C problem. It is known today that
approximately 200 million people worldwide are
infected by HCV [1]. The main transmission route of
HCV is parenteral [1-3]; however, approximately 10%
of the cases are sporadic, without well-defined
transmission routes [4,5].
The populations most affected by HCV are
patients that undergo multiple blood transfusions,
individuals who are intravenous and inhalant drug
users, hemophiliacs, and hemodialysis patients [1,5].
The high prevalence of HCV infections in patients
that undergo hemodialysis has been described
worldwide [6-10].
Mosconi [11], in an analysis of 185 serum samples
of chronic renal patients from Bologna, Italy, utilizing
ELISA and second-generation Immunoblotting (IB)
tests, observed HCV infection in 38% of them. The
number of transfusions and the duration of dialysis
affected the prevalence rates in this population.
Hayashi [12], in a serum-epidemiological study,
undertaken in two cities in Japan, analyzed the serum
of hemodialysis patients and compared them to the
general population. They observed a prevalence of
3.3% for the general population of Fukuoka and of
51.6% in the hemodialysis patients, while in Okinawa,
the rates were 0.4% and 9.1% for the general
population and hemodialysis patients, respectively.
Pujol [7], in a study of four dialysis units in Caracas,
Venezuela, observed alarming prevalence and incidence
rates of HCV. The observed prevalence rate was 71%
and the incidence rate, in the period between 1994
and 1995, was 38%.
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Tokars [9] carried out a national vigilance study in
dialysis centers in the United States in 1995. There
were 2,647 centers, totaling 244,954 patients, and the
prevalence of HCV was 10.4%.
The cause for the elevated prevalence of HCV
infection in hemodialysis patients may be due to the
excessive number of transfusions that these patients are
frequently submitted to [13], and since the prevalence
increases with the duration of dialysis treatment, there
is an indication that the environment itself functions as
a vehicle in the dissemination of the virus among the
patients in dialysis centers [14-19].
Medin [20] did a retrospective study with 236
patients in dialysis centers in Stockholm, and he
determined the period of serological conversion for HCV
in 23 patients, emphasizing that 80% of them had
undergone blood transfusion. He raised the hypothesis
that the number of transfusions is not always trustworthy,
due to the fact that patients often receive transfusions in
other services, not notifying this fact in the local unit.
Some studies [20,21] on patients positive and
negative for anti-HCV did not find a correlation
between dissemination of the virus in the dialysis units
and sharing of the machines or rooms between the
patients. In other reports, there was a lower incidence
of infection in the units that use separate machines and
rooms for patients that test positive for anti-HCV
[15,22-26]. Dos Santos [26] observed a lower
incidence in the centers that separate patients who are
positive for anti-HCV and in those that use separate
rooms for the reutilization of the dialyzers.
Hepatitis C virus does not penetrate the membrane
pores of the dialyzer; the size of the virus is 10 times
greater than the dialysis membrane pores [19].
However, the virus could pass if an accidental rupture
of the membrane occurs [6,27,28].
Cendoroglo-Neto [17], in a study made on serum
samples of 185 patients that had undergone
hemodialysis and on 124 patients in treatment with
Continuous Ambulatory Peritoneal Dialysis (CAPD),
observed a significant difference in the prevalence of
infections by the Hepatitis B and C viruses between
the two groups. The duration of hemodialysis treatment,
the number of transfusions and the environment were
the main factors determining the risk for Hepatitis B
and C transmission, which explains the high infection
prevalence in hemodialysis patients compared to those
who undergo CAPD.
Morales [29], in a study concerning the prevalence
and incidence of infection by HCV in hemodialysis,
observed that 70% of the patients positive for anti-
HCV had undergone blood transfusion. Sayiner [8]
carried out a study in Turkey that compared patients in
hemodialysis with those on CAPD treatment. They
observed a 6.8% anti-HCV prevalence in CAPD
patients, while the hemodialysis patients had a
prevalence of 45.7%. The duration of dialysis, the
number of transfusions, as well as the number of units
of blood received, were the principal factors
contributing to the elevated prevalence among
hemodialysis patients.
Sandhu [30], in a study done in Canada in 1999,
observed that the factors most frequently related to
the condition of the HCV infection carrier are the
duration of dialysis treatment, ALT alterations for more
than six months, and history of transplants prior to 1990.
Blood transfusion, by itself, was not an important factor
for the dissemination of the infection.
Basic biosafety measures are recommended for all
dialysis centers, with the aim of protecting the patients
and employees. These basic measures were
recommended by the CDC (1988), with the goal of
minimizing the dissemination of blood-transmitted agents
in the dialysis units, including Hepatitis B and C viruses.
De Lamballerie [31], in a study concerning nosocomial
transmission of HCV in patients submitted to
hemodialysis, observed some important factors in the
dissemination of this agent in several centers. The main
factors were immunodeficiency in chronic renal
patients, invasive procedures, which are frequent in
these patients, and blood transfusion.
Several authors cite as a risk for HCV
dissemination between patients, hemodialysis sessions
in the same room, in the same time-period or in
adjacent rooms, with patients who are carriers of HCV
infection [15,22-26].
In a study carried out in dialysis centers in Belgium,
Jadoul [32] reported, based on the analysis of 15 units
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that had been followed up for 54 months, a reduction
in the incidence of hepatitis C virus infection, with the
incidence tending to zero. The only changes were the
universal biosafety measures recommended by the
CDC.
Hemodialysis treatment in Brazil began in 1950,
with the implementation of the dialysis service and the
first kidney transplant. In 1960, Nephrology was
included as a distinct discipline in clinical medicine,
followed by the creation of the Brazilian Society of
Nephrology [33].
In 1996, the Brazilian Health Ministry published a
directive, establishing rules for the functioning of the
substitutive renal therapy services, taking into account
the necessity of defining a standard of quality and safety,
and aiming at the reduction of morbidity and mortality
rates. This directive determined that serology for
Hepatitis B and C be done on a monthly basis, along
with biochemical evaluations, such as ALT
determination [34]. This directive was published for a
second time in 2000 [35].
Even with the implementation of the standards and
biosafety rules, the prevalence of infection by HCV in
patients submitted to hemodialysis treatment continues
to be high. In order to reduce this quotient, we need to
understand the dissemination dynamics of this virus in
the dialysis units. Lowering the incidence rates of
infection is a goal for professionals involved in the study
of viral Hepatitis throughout the world.
Moraes [6] performed a case-control study on 813
patients undergoing dialysis and on 772 apparently
healthy adult individuals considered as controls, in the
state of Santa Catarina, Brazil. The observed prevalence
of HCV was 33.4% for the patients and 0.8% for the
controls. Besides these populations, data was obtained
on the employees of the dialysis units, with an observed
prevalence of 2.7% for this third group. The most frequent
genotypes were: 1b, 3a, and 1a.
Prevalence data for patients submitted to
hemodialysis in Brazil varied from 23.8% in the
Northeastern region, to 45.5% in the Northern region,
and 46.7% in the Midwest region. The mean
prevalence in the population in the Southeast region
was 35.3% [36,37].
Santana [38], in a study involving 395 patients
submitted to hemodialysis, in different units in the city
of Salvador, Bahia, Brazil, collected information
regarding the number of blood transfusions in 75.4%
of the patients; He concluded that the positivity of anti-
HCV increases with the number of transfusions. Among
these 298 patients, 48 had not received blood and 6
(12.5%) of these tested anti-HCV positive. Of the 250
that had already received at least one transfusion, 64
(25.6%) were anti-HCV positive. The prevalence
found in this study (23.8%) was roughly 13 times greater
than that estimated for blood donors (1.7%) in this
municipal district.
Moreira [39], in a prospective study, observed a
14.6% prevalence of HCV infection and an incidence
of 3.1/1000 affected individuals/month, in an analysis
of chronic renal patients from two dialysis centers in
the metropolitan region of São Paulo, Brazil. Simmonds
[40], using ELISA and 2nd generation IB tests,
performed antibody detection on 217 patients
undergoing hemodialysis. They observed a 97.5%
concordance between the two methods.
Al Meshari [41] demonstrated that
immunoenzymatic tests can fail in the detection of
hemodialysis patients who are carriers of HCV
infection; an explanation for this fact would be the weak
immune response of chronic renal patients to a great
variety of antigenic stimuli or to the uremic condition
itself. According to Tokars [9], the immunoenzymatic
test fails to detect 10% of the infected patients.
Even with the use of 3rd generation tests, false
negative and false positive results are still observed.
The immunoenzymatic tests may fail to detect individuals
with active HCV infection. During the acute phase of
the disease, anti-HCV antibodies are not detected by
any test developed thus far. Among the chronic renal
patients, with known immune disorders, the
seronegativity period may be even more ample. The
incorporation of the viral envelope proteins could be
an alternative for the development of more sensitive,
new immunoenzymatic tests. However, due to the
existence of hyper-variable regions in these proteins,
the intrinsic difficulties in developing these tests may
never be surpassed [42].
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Moraes [6], in a study made on hemodialysis
patients in the state of Santa Catarina, Brazil, using
ELISA and IB antibody detection techniques, both 3rd
generation, found a 98.2% concordance between the
two methods. The IB test has high specificity, providing
separately-reacting antibodies for each viral antigen,
therefore being important for the confirmation of positive
serology obtained in the ELISA test. The IB test is not
routine in hemodialysis units, , probably because of its
high cost, and its difficult execution and interpretation.
Its incorporation as a complementary test to the ELISA
may reduce the errors observed in the screening of the
patients, thus avoiding the false positive and false
negative results.
Molecular biology techniques are the most efficient
tools for the identification of HCV strains, useful both
for diagnosis and for viral characterization studies. The
Polymerase Chain Reaction (PCR) techniquewhen
used for HCV infection, allows the identification of the
acute phase of the infection. This is very important,
considering that anti-HCV antibodies are not detected
during this phase. Furthermore, the detection of
antibodies does not differentiate between past and
present infections. Consequently, both PCR and
serology cannot distinguish acute from chronic cases
[41]. Nevertheless, the separation of HCV-infected
patients from HCV carriers, as is done with HBV
infected patients and HBV carriers, is still controversial.
Umlauft [43], in a study focusing on Hepatitis C viremia
standards in patients that have undergone hemodialysis,
in seven dialysis centers in Austria and one in Northern
Italy, observed fluctuation in the degree of viremia in
one-third of the patients with positive PCR, with
periods of up to four weeks of undetectable HCV-
RNA. Pujol [7] also observed that ALT levels do not
help in the screening of HCV carriers in dialysis centers.
Schneeberger [44], in an HCV infection vigilance study
in dialysis centers in Holland, observed that of the 2,576
samples with negative serology, six had HCV RNA.
According to these authors, the PCR, along with
antibody detection, should be “gold standards” for the
diagnosis of HCV in dialysis centers. They emphasize
that among patients submitted to hemodialysis, various
causes can provoke alterations in the serum levels of
aminotransferases, which makes these tests relatively
unspecific [45].
Carneiro [37] demonstrated, in a study of 428 patients
conducted in the central region of Brazil, that 10.3% of
the patients that tested negative for HCV were HCV-
RNA positive. He concluded that PCR should be
included in the screening of hemodialysis patients.
Moreira [39] observed that the monthly
determination of ALT does not aid in the early detection
of HCV infection. The values that were observed were
within the normal upper limit for ALT in both carrier
patients and non-carrier patients. Izopet [23], in a
prospective study of hemodialysis patients, did not
identify any patient with negative serology using ELISA,
yet had positive results using PCR.
Piazza [46] in an HCV vigilance study, starting in
1992, observed that 72% of the patients with positive
serology also tested positive with PCR. Five years later,
continuing with the same program, they observed similar
results (75%). Sterling [47] did not observe a
correlation between ALT alteration, viral load, or
hepatic histology, in patients with terminal renal disease
and HCV infection.
The false negative results may place HCV-infected
patients in contact with chronic renal patients negative
for this agent, while false positive results may result in
the exposure of HCV-negative patients. We should bear
in mind that patients who undergo hemodialysis, often
not only share the same room, but also the same
machines, and though the virus does not penetrate the
filters, it could accidentally pass through the membranes
and contaminate these machines, placing at risk patients
who undergo therapy with the same unit.
Careful and adequate laboratory practices, such as
the incorporation of more than one diagnostic technique,
such as the IB and PCR tests, and serology in more
than one serum sample could help avoid false positive
and negative results. Since PCR detects RNA and
indicates the presence of circulating antigen in the
affected individual, it could be the technique of choice
as a complementary test to serology, allowing the
detection of viremia in a period prior to serologic
conversion, as has been demonstrated by several
studies [39].
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Molecular studies on HCV have contributed to
various epidemiological studies, and in an attempt to
study HCV dissemination in dialysis centers, several
researchers have used genotyping techniques for the
characterization of circulating viral strains. Allander et
al. [14] were the first to determine the similarity of the
nucleotide sequence among hemodialysis patients, to
characterize HCV dissemination among them. They
observed that 5 out of 14 patients with positive serology
for HCV had been contaminated with the same viral
strain, and that two other patients had been infected
with two strains from different genotypes. These patients
did not receive blood transfusions and did not share
the same dialysis machine, however they shared the
same room. They used  sequencing of the E2/NS1
region to characterize the nosocomial transmission of
HCV in a dialysis unit. De Lamballerie [31]
characterized nosocomial transmission by the
identification of the circulating HCV genotypes in a
dialysis center, through characterization of the viral
envelope region.
Norder et al. [48], analyzed the NS5B genomic
segment to determine the HCV transmission chain in
hemodialysis patients. They demonstrated the
transmission chain by characterizing the strains and the
source of contamination, by analyzing serum from
patients who presented serologic conversion during the
study and through serum analysis of nurses who worked
in the respective centers.
Mizuno [49], also using molecular characterization
techniques, detected the dissemination of HCV in two
dialysis centers in Japan. By sequencing the hyper-
variable 1 region, they made a phylogenetic and
serological study of the viral strains, determining
transmission routes between patients.
In a study carried out by Fabrizi [50], a
predominance of the 2a genotype was observed,
followed by the 1b genotype and genotypes 3 and 4,
which were observed in 3.0% of the population. This
data differed from that observed in the general
population and in other epidemiological studies done
in Italy.
Zein [51] emphasized that the differences between
the genotypes may affect the diagnostic tests, especially
in regions where there is a high prevalence of genotypes
different from 1a, which is used in tests throughout the
world, causing high rates of false negative results.
Busek [52] in a study done in the city of Belo
Horizonte, Minas Gerais, Brazil, reported a prevalence
of 20.3% for anti-HCV; this was 4.6 times greater than
the prevalence of Hepatitis B virus (4.4%). In this same
study, the HCV genotypes were determined for 83
patients positive for HCV-RNA; 66% belonged to
genotype 1, 24% to genotype 2 and 7.2% to genotype
3. Genotype 4 was only found in one patient. They
concluded that the use of multiple dialysis units, the
total duration of the treatment, and the high number of
blood transfusions were important factors that
determined HCV contamination.
Moreira [39] examined the dissemination of HCV
in dialysis centers in the city of São Paulo, SP, Brazil,
looking for predominance of a single genotype in
patients who underwent the procedure in the same
dialysis unit. They detected genotype 4 HCV, which is
rare in this country, in two patients who underwent
treatment in the same period/shift and in machines that
were near each other.
The 5’NCR region is the most practical region for
genotyping; but it is the most conserved, so it is not the
best region to establish transmission chains within
dialysis units, even though it is possible to identify all
the amplified samples.
The PCR method can be used for the verification
of false positive and negative results, for the early
diagnosis of HCV infection, as well as for determining
the circulation of viral strains belonging to the same
genotype, confirming the presence of the Hepatitis C
virus in hemodialysis environments.
There is a need for more studies and for the
implementation of preventive and control measures of
this infection in chronic renal patients.. Epidemiological
studies and the continuous follow-up of Hepatitis C
virus infection in dialysis units are of great importance
for public health throughout the world. These should
include implementation of new methodologies and
improvement of the infrastructure of the centers; these
measures could help improve the quality of life of
dialysis patients.
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